Triangle Coviracil Study Completion Funded Via $100 Mil. Equity Facility
Executive Summary
Triangle Pharmaceuticals' $100 mil. equity facility appears to be sufficient to finance the company until it completes clinical development of the HIV nucleoside analogue Coviracil (emtricitabine).